Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Carcinoma, Hepatocellular 9Esophageal Neoplasms 7Stomach Neoplasms 4Small Cell Lung Carcinoma 4Rectal Neoplasms 4Nasopharyngeal Carcinoma 4Colorectal Neoplasms 4Neoplasms 3Esophageal Squamous Cell Carcinoma 3Colonic Neoplasms 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Hodgkin Disease 2Glioblastoma 2mCRPC 1Uterine Cervical Neoplasms 1Unresectable Stage III Non-small Cell Lung Cancer 1Tongue Squamous Cell Carcinoma 1SCLC, Extensive Stage 1Rare Tumour 1Non-Muscle Invasive Bladder Neoplasms 1Non Squamous Non-small Cell Lung Cancer 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1NSCLC 1MSI-H Colorectal Cancer 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1

Interventions

Oxaliplatin 4Capecitabine 3Radiotherapy 2Docetaxel 2Androgen Antagonists 2tislelizumab 1pembrolizumab 1luprolide acetate gel depot 1lenvatinib 1enzalutamide 1cemiplimab 1Surgical Procedures, Operative 1Radiotherapy, Image-Guided 1Poly(ADP-ribose) Polymerase Inhibitors 1PF06821497 1Negative-Pressure Wound Therapy 1Leuprolide 1Leucovorin 1Injections 1Fluorouracil 1Drug Therapy 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Adenocarcinoma × tislelizumab × Clear all
NCT07385703 2026-02-04

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Not yet recruiting
752 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡